In its latest quarter, Intuitive Surgical reported revenue of $2.87 billion, up 18.8% year-over-year, and non-GAAP earnings per share of $2.53, beating the consensus estimate by $0.26. The company installed a record number of da Vinci surgical systems during the period, driving consumables and services revenue growth of 21%. However, management provided guidance below street expectations for the upcoming quarter, projecting system placements to moderate and consumables growth in the mid-teens percent range. Investors will be watching whether intake from recently cleared procedures can offset the conservative outlook on core robotics deployments.

Regulators expanded the approved use of the latest da Vinci 5 platform to include select advanced cardiac surgeries, significantly broadening the addressable market for both system sales and recurring instrument revenue. The new indication is expected to add a multi-hundred-million-dollar revenue tail over the next three to five years as leading cardiac centers adopt robotic-assisted approaches. The clearance also supports Intuitive’s strategic push into higher-acuity specialties, where procedure volumes and per-case instrument utilization are higher than in general surgery.

Alpha Cubed Investments LLC boosted its position by 13.0% during the third quarter, acquiring an additional 10,677 shares to reach 92,600 held, representing 1.4% of its portfolio and valued at $41.4 million. Other funds also raised stakes: Valley Wealth Managers by 52.7% to 4,084 shares; Tandem Investment Advisors by 4.5% to 9,219 shares; Strategic Advisors by 63.3% to 10,397 shares; AE Wealth by 18.9% to 11,556 shares; and LRI Investments by 24.0% to 1,997 shares. Institutional ownership stands at 83.64%. In contrast, directors and executives sold a combined 75,557 shares valued at roughly $42 million over the past quarter, including 27,300 shares by a board member and 18,231 shares by senior executives, signaling potential near-term supply pressure on the stock.

Sell-side support continues to strengthen with multiple firms reaffirming buy ratings and raising price targets, including a recent strong-buy initiation that could attract incremental institutional demand. While some analysts trimmed targets due to valuation concerns, the consensus remains a moderate buy, underpinned by expectations of sustained high-single-digit consumables growth and market share gains in specialty procedures. Mixed valuation commentary may temper short-term momentum, but the long-term thesis around robotic-assisted surgery penetration continues to drive positive conviction among growth-oriented investors.